Download PDF
Semin intervent Radiol 2011; 28(2): 240-245
DOI: 10.1055/s-0031-1280673
© Thieme Medical Publishers

Hepatic Radioembolization Complicated by Gastrointestinal Ulceration

Jeremy Collins1 , Riad Salem1
  • 1Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, Illinois
Further Information

Publication History

Publication Date:
16 June 2011 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Gastric ulceration is a relatively uncommon but well-described complication of yttrium 90 (Y90) radioembolization therapy in the locoregional treatment of hepatic tumors. Meticulous attention to vascular anatomy, an assessment of antegrade hepatic arterial flow, and knowledge of the dynamic embolic effect of the chosen Y90 particulate at treatment are requirements to reduce the risk of nontarget embolization to gastrointestinal structures. Radiation-associated gastrointestinal ulceration is difficult to treat, and may be associated with gastrointestinal bleeding, bowel obstruction, and perforation. Surgical excision of the involved segment with bypass may be necessary. The increased use of coil embolization of at-risk vessels combined with administration of Y90 particulates with minimal embolic effect has reduced the incidence of radioembolization associated gastrointestinal ulceration.

KEYWORDS

Radioembolization - ulceration - complication

REFERENCES

  • 1 Blanchard R J, Morrow I M, Sutherland J B. Treatment of liver tumors with yttrium-90 microspheres alone.  Can Assoc Radiol J. 1989;  40 (4) 206-210
    PubMedGoogle Scholar
  • 2 Carretero C, Munoz-Navas M, Betes M et al.. Gastroduodenal injury after radioembolization of hepatic tumors.  Am J Gastroenterol. 2007;  102 (6) 1216-1220
    CrossrefPubMedGoogle Scholar
  • 3 South C D, Meyer M M, Meis G et al.. Yttrium-90 microsphere induced gastrointestinal tract ulceration.  World J Surg Oncol. 2008;  6 93
    CrossrefPubMedGoogle Scholar
  • 4 Murthy R, Brown D B, Salem R et al.. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy.  J Vasc Interv Radiol. 2007;  18 (4) 553-561, quiz 562
    CrossrefPubMedGoogle Scholar
  • 5 Riaz A, Lewandowski R J, Kulik L M et al.. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review.  J Vasc Interv Radiol. 2009;  20 (9) 1121-1130, quiz 1131
    CrossrefPubMedGoogle Scholar
  • 6 Kennedy A S, Coldwell D, Nutting C et al.. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience.  Int J Radiat Oncol Biol Phys. 2006;  65 (2) 412-425
    CrossrefPubMedGoogle Scholar
  • 7 Szyszko T, Al-Nahhas A, Tait P et al.. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres.  Nucl Med Commun. 2007;  28 (1) 21-24
    CrossrefPubMedGoogle Scholar
  • 8 Salem R, Thurston K G. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics.  J Vasc Interv Radiol. 2006;  17 (9) 1425-1439
    CrossrefPubMedGoogle Scholar
  • 9 Carr B I. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.  Liver Transpl. 2004;  10 (2, Suppl 1) S107-S110
    CrossrefPubMedGoogle Scholar
  • 10 Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere).  Psychooncology. 2004;  13 (2) 73-79
    CrossrefPubMedGoogle Scholar

Riad SalemM.D. 

Department of Radiology, Northwestern University, 676 North St. Clair Street

Suite 800, Chicago, IL 60611

Email: r-salem@northwestern.edu

      >